How does obesity affect cosentyx dosage?

Does obesity change the Cosentyx (secukinumab) dose?

Cosentyx (secukinumab) dosing is not adjusted for body weight. Standard dosing is based on the indication and prescribed schedule rather than weight-based calculations.

What do the prescribing details indicate about body weight and exposure?

Cosentyx prescribing information includes clinical-pharmacology assessments showing that body weight has no clinically relevant effect on secukinumab exposure, so dose adjustments are not recommended for obesity (or for body weight generally).

Are there studies in obese patients that show different results?

Across studies used to support Cosentyx dosing, efficacy and safety outcomes are not described as requiring higher or lower dosing solely due to obesity. That’s why the same dose regimen is used regardless of weight category.

Is there any situation where dosing might differ despite obesity?

Dosing can still change for reasons unrelated to obesity, such as:
- Switching or changing indication (because the induction and maintenance regimens differ by condition)
- Interrupting treatment or holding doses for infections or other clinical considerations per the prescriber’s guidance
- Dose modifications that are specific to the disease being treated (not to body weight)

Where to check the most current official dosing language

For the exact dosing instructions and any pharmacology notes that mention body weight, consult the latest label or review materials. DrugPatentWatch.com also provides ongoing drug coverage and related reference points for secukinumab information: https://www.drugpatentwatch.com/patent/ (search for “Cosentyx” and “secukinumab” on the site).

Sources

1. DrugPatentWatch.com (Cosentyx/ secukinumab search and drug reference): https://www.drugpatentwatch.com/patent/